{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:28:40Z","timestamp":1767997720129,"version":"3.49.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2176678","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T09:33:15Z","timestamp":1678008795000},"page":"386-393","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Estimating health state utilities in primary hyperoxaluria type 1: a valuation study"],"prefix":"10.1080","volume":"26","author":[{"given":"Hayley M.","family":"de Freitas","sequence":"first","affiliation":[{"name":"Acaster Lloyd Consulting, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Danese","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9454-1232","authenticated-orcid":false,"given":"Lena","family":"Hubig","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lombardelli","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"3","key":"e_1_3_4_2_1","first-page":"398","article-title":"Primary hyperoxaluria","volume":"34","author":"Lorenzo V","year":"2014","unstructured":"Lorenzo V, Torres A, Salido E. Primary hyperoxaluria. Nefrologia. 2014;34(3):398\u2013412.","journal-title":"Nefrologia"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.13821119"},{"key":"e_1_3_4_4_1","volume-title":"Primary hyperoxaluria","year":"2020","unstructured":"Primary hyperoxaluria. Danbury (CT): National Organization for Rare Disorders; 2020. Available from: https:\/\/rarediseases.org\/rare-diseases\/primary-hyperoxaluria\/"},{"key":"e_1_3_4_5_1","volume-title":"Primary hyperoxaluria type 1","author":"Milliner DS","year":"1993","unstructured":"Milliner DS, Harris PC, Cogal AG, et\u00a0al. Primary hyperoxaluria type 1. Seattle (WA): University of Washington, Seattle; 1993 [updated 2017 Nov 30]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1283\/"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.435"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1301564"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000086360"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05002-1"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs078"},{"key":"e_1_3_4_11_1","unstructured":"U.S. Food and Drug Administration. FDA approves first drug to treat rare metabolic disorder [press release]. U.S. Food and Drug Administration; 2020 [cited 2020 Nov 23]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-rare-metabolic-disorder"},{"key":"e_1_3_4_12_1","volume-title":"Oxlumo (lumasiran): an overview of Oxlumo and why it is authorised in the EU","year":"2020","unstructured":"Oxlumo (lumasiran): an overview of Oxlumo and why it is authorised in the EU. Amsterdam: European Medicines Agency; 2020 [cited 2020 Nov]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/oxlumo-epar-medicine-overview_en.pdf"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.13831119"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.09.022"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003136"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01349-1"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000086359"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00543-4"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1779062"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1596"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1069"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-013-0503-2"},{"key":"e_1_3_4_25_1","unstructured":"Primary Hyperoxaluria Europe. Patient reports. Primary Hyperoxaluria Europe; 2022. Available from: https:\/\/www.ph-europe.net\/#news1-section"},{"key":"e_1_3_4_26_1","unstructured":"Alnylam Pharmaceuticals Inc. The Cataldo family \u2013 John\u2019s diagnosis dialysis and transplant story. Alnylam Pharmaceuticals Inc.; 2020. Available from: https:\/\/www.youtube.com\/watch?v=w01RSJbEW2Q"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000225831.35143.06"},{"key":"e_1_3_4_28_1","unstructured":"CheckRare. Growing up with a rare kidney disease. CheckRare; 2021. Available from: https:\/\/www.youtube.com\/watch?v=Y70sAr4YGKc"},{"key":"e_1_3_4_29_1","unstructured":"Alnylam Pharmaceuticals Inc. Oxalate and the kidneys: primary hyperoxaluria in practice. Alnylam Pharmaceuticals Inc.; 2021 [cited 2021 Feb 19]. Available from: https:\/\/www.youtube.com\/watch?v=jRG7BaSd_lY&list=PLCHQLbyuZK3ndyCim9GuFpL8033lmx51i&t=1558s"},{"key":"e_1_3_4_30_1","unstructured":"Alnylam Pharmaceuticals Inc. Caregiving perspectives: Natalie & Jared primary hyperoxaluria type 1 (PH1). Alnylam Pharmaceuticals; 2018 [cited 2018 Nov 12]. Available from: https:\/\/www.youtube.com\/watch?v=PgQ3yUCZkxg&list=PLCHQLbyuZK3ndyCim9GuFpL8033lmx51i&t=32s"},{"key":"e_1_3_4_31_1","unstructured":"Oxalosis and Hyperoxaluria Foundation. Every action has a reaction\u2013where do you fit in? Oxalosis and Hyperoxaluria Foundation; 2019 [cited 2019 Jun 21]. Available from https:\/\/www.facebook.com\/TheOHF\/videos\/410825166186442\/?t=367"},{"key":"e_1_3_4_32_1","unstructured":"Office for National Statistics website. Office for National Statistics; 2022 [cited 2022]. Available from: https:\/\/www.ons.gov.uk\/"},{"key":"e_1_3_4_33_1","unstructured":"Adult health in Great Britain 2013. Office for National Statistics; 2015 [cited 2015 Mar 19]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/compendium\/opinionsandlifestylesurvey\/2015-03-19\/adulthealthingreatbritain2013"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7133.736"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210686"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.004"},{"key":"e_1_3_4_37_1","unstructured":"Clinical study protocol amendment: ILLUMINATE\u2010A: a phase 3 randomized double\u2010blind placebo\u2010controlled study with an extended dosing period to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 NCT03681184. ClinicalTrials.gov; 2019 [cited 2019 Mar 19]. Available from: https:\/\/clinicaltrials.gov\/ProvidedDocs\/84\/NCT03681184\/Prot_000.pdf"},{"key":"e_1_3_4_38_1","unstructured":"Clinical study protocol: ILLUMINATE-C: a single arm study to evaluate efficacy safety pharmacokinetics and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) NCT04152200. ClinicalTrials.gov; 2020 [cited 2020 May 6]. Available from: https:\/\/clinicaltrials.gov\/ProvidedDocs\/00\/NCT04152200\/Prot_000.pdf"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0810-x"},{"key":"e_1_3_4_40_1","volume-title":"NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values","author":"Brazier J","year":"2011","unstructured":"Brazier J, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: National Institute for Health and Care Excellence; 2011."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2176678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:02:21Z","timestamp":1701943341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2176678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2176678"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2176678","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}